Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Rocuronium and Org 25969 With Cisatracurium and Neostigmine (19.4.310)(P05931)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects of ASA 1 - 4;~* Subjects above or equal to the age of 18;~* Scheduled for surgical procedures with a general anesthesia requiring neuromuscular relaxation with the use of rocuronium or cisatracurium;~* Scheduled for surgical procedures in supine position;~* Given written informed consent.~Exclusion Criteria:~* Subjects in whom a difficult intubation because of anatomical malformations was expected;~* Subjects known or suspected to have neuromuscular disorders impairing neuromuscular block (NMB) and/or significant renal dysfunction;~* Subjects known or suspected to have a (family) history of malignant hyperthermia;~* Subjects known or suspected to have an allergy to narcotics, muscle relaxants or other medication used during general anesthesia;~* Subjects receiving medication in a dose and/or at a time point known to interfere with neuromuscular blocking agents such as antibiotics, anticonvulsants and Mg2+;~* Subjects in whom the use of neostigmine and/or glycopyrrolate may be contraindicated;~* Subjects who had already participated in an Org25969 trial;~* Subjects who had participated in another clinical trial (not pre-approved by NV Organon) within 30 days of entering into CT 19.4.310.~* Female subjects who are pregnant:~* Female subjects of childbearing potential not using any method of birth control: condom or using only hormonal contraception as birth control;~* Female subjects who were breast -feeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sugammadex (Type: EXPERIMENTAL): 2.0 mg/kg Org 25969 (sugammadex)
- Neostigmine (Type: ACTIVE_COMPARATOR): 50 ug/kg neostigmine

Based on this trial design, predict the completion outcome and termination type (if applicable).